Group 1 - The stock of Luye Pharma Group (博安生物) increased by nearly 5%, reaching HKD 9.12 with a trading volume of HKD 358 million as of the report time [1] - On January 21, Luye Pharma announced that its board was informed by its controlling shareholder, Luye Pharma Group, about a plan to transfer 38.5 million H-shares to the market through its wholly-owned subsidiary, Shandong Luye Pharmaceutical Co., Ltd., on January 22, 2026 [1] - Luye Pharma previously acquired 98% of the shares of Luye Geneora Holding Limited, integrating its antibody drug pipeline, technology platform, and production assets, with Shandong Luye Pharmaceutical Co., Ltd. becoming the core holding entity [1] Group 2 - By 2025, Shandong Luye Pharmaceutical Co., Ltd. is expected to hold 70.81% of Luye Pharma's shares [1] - Luye Pharma serves as a key vehicle for Luye Pharma Group's transition from traditional small molecules to biopharmaceuticals, aiding in the establishment of a dual research and development system for "chemical drugs + biological drugs" [1]
博安生物涨近5% 山东绿叶制药拟向Luye Geneora Holding进一步转让公司H股